아래 문헌은 모두 PubMed E-utilities로 PMID를 조회하여 제목·저자·연도·저널을 NCBI 기록에서 그대로 가져온 것입니다. 사람이 기억으로 적은 인용은 없습니다. 각 항목의 PMID 링크는 실제로 그 논문으로 연결됩니다.

모델 파일과의 대응:

1. Nucci M (2009). Fungal infections in hematopoietic stem cell transplantation and solid-organ transplantation--focus on aspergillosis. Clin Chest Med. PMID 19375636
2. Kontoyiannis DP (2010). Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. PMID 20218877
3. Pappas PG (2010). Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. PMID 20218876
4. Brown GD (2012). Hidden killers: human fungal infections. Sci Transl Med. PMID 23253612
5. Denning DW (2016). Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. PMID 26699723
6. Ullmann AJ (2018). Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. PMID 29544767
7. Latgé JP (2019). Aspergillus fumigatus and Aspergillosis in 2019. Clin Microbiol Rev. PMID 31722890
8. Cadena J (2021). Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infect Dis Clin North Am. PMID 34016284
9. Denning DW (2024). Global incidence and mortality of severe fungal disease. Lancet Infect Dis. PMID 38224705

10. Schaffner A (1982). Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest. PMID 7037853
11. Garlanda C (2002). Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. PMID 12432394
12. Philippe B (2003). Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect Immun. PMID 12761080
13. Schrettl M (2004). Siderophore biosynthesis but not reductive iron assimilation is essential for Aspergillus fumigatus virulence. J Exp Med. PMID 15504822
14. Dagenais TR (2009). Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis. Clin Microbiol Rev. PMID 19597008
15. Werner JL (2009). Requisite role for the dectin-1 beta-glucan receptor in pulmonary defense against Aspergillus fumigatus. J Immunol. PMID 19342673
16. Kwon-Chung KJ (2013). Aspergillus fumigatus--what makes the species a ubiquitous human fungal pathogen?. PLoS Pathog. PMID 24348239
17. Latgé JP (2017). The Cell Wall of the Human Fungal Pathogen Aspergillus fumigatus: Biosynthesis, Organization, Immune Response, and Virulence. Annu Rev Microbiol. PMID 28701066

18. Gerson SL (1984). Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. PMID 6696356
19. Feldmesser M (2006). Role of neutrophils in invasive aspergillosis. Infect Immun. PMID 17030575
20. Segal BH (2009). Aspergillosis. N Engl J Med. PMID 19403905
21. Bruns S (2010). Production of extracellular traps against Aspergillus fumigatus in vitro and in infected lung tissue is dependent on invading neutrophils and influenced by hydrophobin RodA. PLoS Pathog. PMID 20442864
22. Price TH (2015). Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. PMID 26333778

23. Marr KA (2002). Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. PMID 11880955
24. Lionakis MS (2003). Glucocorticoids and invasive fungal infections. Lancet. PMID 14654323
25. Bochud PY (2008). Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. PMID 18946062
26. Cunha C (2010). Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood. PMID 20807886
27. Lanternier F (2013). Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med. PMID 24131138
28. Ghez D (2018). Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. PMID 29437588

29. Caillot D (1997). Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. PMID 8996135
30. Caillot D (2001). Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. PMID 11134220
31. Kontoyiannis DP (2002). Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis. PMID 11957017
32. Greene RE (2007). Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. PMID 17205443
33. Chamilos G (2008). Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. PMID 18611163
34. Liu H (2016). Aspergillus fumigatus CalA binds to integrin α(5)β(1) and mediates host cell invasion. Nat Microbiol. PMID 27841851

35. Mennink-Kersten MA (2004). Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. PMID 15172343
36. Maertens J (2005). Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. PMID 16206097
37. Marr KA (2005). Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. PMID 15909264
38. Pfeiffer CD (2006). Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. PMID 16619154
39. Karageorgopoulos DE (2011). β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. PMID 21367728
40. White PL (2015). Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative. J Clin Microbiol. PMID 26085618
41. Husain S (2018). A strategy for prevention of fungal infections in lung transplantation: Role of bronchoalveolar lavage fluid galactomannan and fungal culture. J Heart Lung Transplant. PMID 29548625

42. Purkins L (2002). Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. PMID 12121931
43. Lutsar I (2003). Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. PMID 12942409
44. Pascual A (2008). Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. PMID 18171251
45. Crandon JL (2009). Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother. PMID 19770284
46. Dolton MJ (2014). Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chemother. PMID 24554646
47. Owusu Obeng A (2014). CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?. Pharmacotherapy. PMID 24510446
48. Moriyama B (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. PMID 27981572

49. Cornely OA (2007). Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. PMID 17251531
50. Ullmann AJ (2007). Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. PMID 17251530
51. Jang SH (2010). Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther. PMID 20505665
52. Miceli MH (2015). Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis. PMID 26179012
53. Maertens JA (2016). Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. PMID 26684607
54. Desai AV (2017). Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. Antimicrob Agents Chemother. PMID 28923872
55. Maertens JA (2021). Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. PMID 33549194

56. Adler-Moore J (2002). AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother. PMID 11801577
57. Walsh TJ (2002). Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. PMID 11807146
58. Denning DW (2003). Echinocandin antifungal drugs. Lancet. PMID 14550704
59. Maertens J (2006). Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis. Int J Antimicrob Agents. PMID 16701980
60. Cornely OA (2007). Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. PMID 17443465
61. Marr KA (2015). Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. PMID 25599346
62. Perlin DS (2015). Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci. PMID 26190298

63. Chowdhary A (2012). Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR₃₄/L98H mutations in the cyp51A gene in India. PLoS One. PMID 23285210
64. Fraczek MG (2013). The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. PMID 23580559
65. van der Linden JW (2013). Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. PMID 23667263
66. Verweij PE (2015). International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. PMID 26282594
67. Meis JF (2016). Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc Lond B Biol Sci. PMID 28080986
68. Lestrade PP (2019). Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study. Clin Infect Dis. PMID 30307492

69. Venkataramanan R (2002). Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother. PMID 12183280
70. Sansone-Parsons A (2007). Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. PMID 17542765
71. Brüggemann RJ (2009). Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. PMID 19361301
72. Groll AH (2017). Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults. Clin Pharmacol Drug Dev. PMID 27273343

73. Wingard JR (1999). Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. PMID 10585786
74. Tan K (2006). Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. PMID 16432276
75. Wermers RA (2011). Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. PMID 21239842
76. Epaulard O (2013). A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis. PMID 24046296

77. Oliver JD (2016). F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci U S A. PMID 27791100
78. Gebremariam T (2019). Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. PMID 31685475
79. Hoenigl M (2021). The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. PMID 34626339
80. Thompson GR 3rd (2023). Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. PMID 36442484

81. Meersseman W (2004). Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. PMID 15229094
82. Guinea J (2010). Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect. PMID 19906275
83. Blot SI (2012). A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. PMID 22517788
84. Schauwvlieghe AFAD (2018). Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. PMID 30076119
85. Verweij PE (2020). Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. PMID 32572532
86. Bartoletti M (2021). Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. Clin Infect Dis. PMID 32719848
87. Koehler P (2021). Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. PMID 33333012

88. Cornely OA (2009). Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. PMID 19066334
89. Wingard JR (2010). Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. PMID 20826719
90. Pagano L (2025). Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. PMID 40200079

91. Andes D (2003). Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. Curr Opin Investig Drugs. PMID 14508883
92. Howard SJ (2011). Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis. PMID 21357943
93. Hope WW (2012). Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother. PMID 22064545
94. Jeans AR (2012). Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. PMID 22825124
95. Lepak AJ (2013). Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. PMID 24100500
96. Seyedmousavi S (2013). Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J Antimicrob Chemother. PMID 23129729
97. Felton T (2014). Tissue penetration of antifungal agents. Clin Microbiol Rev. PMID 24396137
98. Al-Nakeeb Z (2015). Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemother. PMID 25712363
99. Gastine S (2021). Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. Antimicrob Agents Chemother. PMID 33168606

총 99편. 모든 PMID는 99건의 NCBI esummary 응답으로 검증되었습니다.

모델의 다음 요소는 위 문헌으로 직접 보정할 수 없었고, 구조적 가정에서 유도하거나 임상 결과에 맞추어 역산한 값입니다. 모델을 쓰는 사람이 어디를 의심해야 하는지 명시해 둡니다.

• 병소 관류 지수 PERF: 혈관침습으로 인한 병소 내 약물 전달 감소를 정량화한 사람 데이터는 없습니다. 괴사성 병변에서 항진균제 농도가 낮다는 것은 조직 침투 문헌(Felton 2014)이 지지하지만, KPERF_LOSS·PERF_GAMMA는 치료 지연 효과를 재현하도록 설정한 값입니다.
• IMAX_AZOLE = 0.955: 트리아졸이 완전한 성장 억제에 도달하지 못한다는 것은 time-kill 곡선의 정성적 성질이지만, 정확히 0.955라는 값은 임의입니다. 모델의 핵심 주장은 이 값이 아니라 1보다 작다는 사실에만 의존합니다.
• 사망 위험 계수 HAZ_*: Herbrecht 2002·Cornely 2007·Maertens 2016의 12주 사망률에 맞추어 역산했습니다. 개별 항의 상대적 크기는 데이터가 아니라 모델 설계자의 판단입니다.
• 에키노칸딘 단독요법: 호중구감소증 1차 치료로서의 대조 시험이 없습니다. 해당 시나리오는 근거 밖 외삽입니다.